Drugs / AD-214
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05914909 | Jul 2023 → Feb 2024 | chronic kidney disease, interstitial lung disease | AdAlta Limited | Completed | No outcome recorded |
| Phase 1 | NCT04494243 | Aug 2020 → Jan 2021 | gastroesophageal reflux disease | Addpharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04415671 | Jun 2020 → Oct 2021 | interstitial lung disease | AdAlta Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05062876 Comparator | Nov 2021 → Mar 2022 | gastroesophageal reflux disease | Addpharma Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-07-20 | AdAlta Limited | Results AdAlta talks to Bulls N’ Bears on developments for fibrosis sufferers adalta.com.au ↗
New data has demonstrated that we can achieve an effective outcome when dosing every two weeks. |
| 2023-07-13 | AdAlta Limited | Results AdAlta presents at TCN Emerging ASX Gems conference adalta.com.au ↗
Dr Oldham highlights the enhanced partnering opportunity flowing from new data released on 7 July, that favourably links AD-214 preclinical animal studies and Phase I human trial results, supporting efficacy at clinically viable dose regimens. |
| 2021-03-31 | AdAlta Limited | Results AdAlta Investor Briefing 2021 adalta.com.au ↗
In the discussion, Claudia explained AD-214’s excellent safety profile, how AD-214 engages the CXCR4 receptor, and how the results showed that receptor occupancy was sustained at high levels for an extended period of time. |
| 2020-07-06 | AdAlta Limited | Regulatory Moving AD-214 into the clinic: AdAlta’s coming of age moment adalta.com.au ↗
AdAlta recently achieved a transformational milestone, with ethics approval of our phase I human trial for lead candidate AD-214 marking our successful transition to a clinical stage biotechnology company. |
All press releases naming this drug 9 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-01 | Addpharma Inc. | AD-214 식약처 허가 완료 addpharma.co.kr ↗ |
| 2023-08-14 | AdAlta Limited | AdAlta investor briefing – progress of AD-214 Phase I extension study adalta.com.au ↗ |
| 2023-07-20 | AdAlta Limited | AdAlta talks to Bulls N’ Bears on developments for fibrosis sufferers adalta.com.au ↗ |
| 2023-07-13 | AdAlta Limited | AdAlta presents at TCN Emerging ASX Gems conference adalta.com.au ↗ |
| 2022-12-22 | AdAlta Limited | Bioshares: AdAlta prioritises IV formulation for AD-214 adalta.com.au ↗ |
| 2021-03-31 | AdAlta Limited | AdAlta Investor Briefing 2021 adalta.com.au ↗ |
| 2020-07-06 | AdAlta Limited | Moving AD-214 into the clinic: AdAlta’s coming of age moment adalta.com.au ↗ |
| 2018-06-27 | AdAlta Limited | AdAlta’s lead program, AD-214, profiled by Clinical Leader adalta.com.au ↗ |
| 2018-04-18 | AdAlta Limited | AdAlta to advance improved lung fibrosis therapy, AD-214 adalta.com.au ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-214 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04494243 ↗ |
| Action | Inhibit | “antagonise the SDF-1/CXCR4 axis” NCT04415671 ↗ |
| Modality | Protein / enzyme biologic | “AD-214 is a recombinant Fc-fusion protein” NCT04415671 ↗ |
| Route | Intravenous | “When Administered Intravenously” NCT04415671 ↗ |
| Target | CXCR4 | “selectively binds to CXCR4” NCT04415671 ↗ |